Quick Detail
Place of Origin
Brand Name
Jinlan
HS-CODE
-
Package & Delivery Lead Time
Package
1g,10g,20g,
Detailed Description
Description
Aficamten is a next‑generation, oral, selective allosteric inhibitor of cardiac myosin. It binds to the myosin catalytic domain, stabilizes the weak actin‑binding state, and reduces ATPase activity, directly decreasing pathologic hypercontractility and left ventricular outflow tract (LVOT) obstruction in hypertrophic cardiomyopathy (HCM)PMC.
Approved Indications
- Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults
- To improve functional capacity, symptoms, and reduce LVOT gradients
Key Features
- Next‑generation cardiac myosin inhibitor (distinct binding site vs mavacamten)PMC
- Once‑daily oral dosing, steady state in ~2 weeks
- Shorter half‑life (~3–4 days) vs mavacamten, wider therapeutic window
- Rapid onset: reduces LVOT gradients within 2 weeks
- Superior efficacy vs metoprolol in improving exercise capacity & quality of life
- Minimal drug‑drug interaction potential
Applications
API, intermediates, reference standards for R&D, generic registration, and commercial manufacturing.
China [CN] 
Click enlarge Image